Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers.

NCT03595189 | Completed Phase 1

• 2 other identifiers: SP15016-092017-004795-63
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase I, randomized, single-blind, parallel group, placebo-controlled, multi-cohort, first-in-human dose escalation study of a single IV 3-hour administration of Cilastatin as stand-alone in healthy male and female volunteers. The study objectives are: The evaluation of safety and tolerability of single intravenous doses of cilastatin in healthy volunteers administered as a 3-hour infusion. The evaluation of the pharmacokinetic characteristics of Cilastatin after a single 3-hour infusion dose.

Conditions

Dose Finding Study

Outcome Measures

Primary Outcomes (8)

• Number of subjects with adverse events (AEs) and serious adverse events (SAEs)

  From baseline up to follow-up (approximately 7 days after treatment administration).

• Safety measures: Changes in Heart rate values will be assessed for each dose level of cilastatin

  From baseline up to follow-up (approximately 7 days after treatment administration).

• Safety measures: Changes in Blood pressure values will be assessed for each dose level of cilastatin

  From baseline up to follow-up (approximately 7 days after treatment administration).

• Safety measures: Changes in Body temperature values will be assessed for each dose level of cilastatin

  From baseline up to follow-up (approximately 7 days after treatment administration).

• Safety measures: Changes in clinical Laboratory testing will be assessed for each dose level of cilastatin.

  From baseline up to follow-up (approximately 7 days after treatment administration)

• Safety measures: Changes in Electrocardiogram (ECG) parameters will be assessed for each dose level of cilastatin.

  Changes in QTc Interval will be assessed.

  From baseline up to follow-up (approximately 7 days after treatment administration).

• Safety measures: Continuous cardiac monitoring (by a holter monitor) will be assessed for each dose level of cilastatin.

  Changes in electrocardiography heart activity will be assessed.

  From baseline up to 24 h Post-dose

• Assessment of any infusion site reaction

  From baseline up to follow-up (approximately 7 days after treatment administration).

Secondary Outcomes (3)

• Determination of the Area under the curve versus time

  From baseline up to 24 hours post start of drug administration

• Determination of plasma concentrations

  From baseline up to 24 hours post start of drug administration

• Determination of renal clearance

  From baseline up to 24 hours post start of drug administration

Study Arms (4)

Cilastatin Dose 1

EXPERIMENTAL

Starting dose (3g of Cilastatin) Single intravenous administration during 3 hours.

Drug: Cilastatin

Cilastatin Dose 2

EXPERIMENTAL

Dose escalation Single intravenous administration during 3 hours.

Drug: Cilastatin

Cilastatin Dose 3

EXPERIMENTAL

Dose escalation Single intravenous administration during 3 hours.

Drug: Cilastatin

Placebo

PLACEBO COMPARATOR

Saline solution for infusion

Drug: Placebo

Interventions

Cilastatin DRUG

Dose escalation 3-hour single intravenous administration

Also known as: Cilastatin sodium

Cilastatin Dose 1; Cilastatin Dose 2; Cilastatin Dose 3

Placebo DRUG

3-hour single intravenous administration

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female subjects, 18-45 years (inclusive) of age at the time of enrolment.
• Male and female subjects willing and able to give their written consent to participate in the trial after having received information about the study design, the objectives of the project, the possible derivative risks, and their right to withdraw from the study at any time and for any reason.
• Body weight within normal range (Quetelet's index between 19 and 30 expressed as kg/m2 and weigh at least 50 kg and no more than 100 kg inclusive).
• Normal clinical records and physical examination.
• Laboratory tests (hematology, biochemistry and urine analysis) within the range of normal values, per the Biochemistry laboratory reference values of the 'Hospital Universitario La Paz'. Variations may be admitted per the clinical criteria of the clinical investigator.
• Clinically acceptable temperature, blood pressure and pulse rate in supine and standing position (SBP between 100-140 mm Hg/ DBP between 50-90 mm Hg / HR between 50-100 bpm). Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.
• To be able to understand the nature of the study and comply with all their requirements.

You may not qualify if:

• Women of childbearing potential who planned to become pregnant, were pregnant and/or breast-feeding, or did not wish to use an effective contraceptive method (hormonal contraceptives \[implant, patches, oral\]) or double-barrier methods \[any double combination of: IUD, male or female prophylactics with spermicidal gel, diaphragm, contraceptive sponge, cervical cap\]).
• History of alcohol dependence or drug abuse in the last 1 year or daily consumption of alcohol \> 40 g/day for men or 24 g/day for women.
• Heavy consumer of stimulating beverages (\>5 coffees, teas, chocolate or cola drinks per day).
• Background of allergy, idiosyncrasy or hypersensitivity to drugs.
• Intake of any medication within 4 days prior and during visit 2 or Xanthine containing foods or beverages or herbal remedies that could interfere with pharmacokinetics of the study drug, except allowed contraceptive medication for female subjects.
• Positive serology for hepatitis B, C or HIV.
• Background or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, haematological or neurological disease or other chronic diseases.
• Twelve lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc ≥ 440 msec, bradycardia (\<50 bpm) or clinically significant minor ST wave changes or any other abnormal changes on the screening ECG that would interfere with measurement of the QT interval.
• Having undergone major surgery during the previous 6 months.
• Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc.) from 6 months prior to drug administration.
• Participation in another clinical trial during the 3 months preceding the drug administration.
• Donation of blood during the 4 weeks preceding the drug administration.
• Acute illness within four weeks before drug administration.
• Clinically significant abnormal laboratory values (as determined by the PI) at the screening evaluation.
• Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhoea or conditions associated with total or partial obstruction of the urinary tract

Sponsors & Collaborators

• Spherium Biomed: lead
• Hospital Universitario La Paz: collaborator

Study Sites (1)

Clinical Trials Unit, School of Medicine, Universidad Autónoma de Madrid

Madrid, 28029, Spain

Location

Related Publications (2)

• Faubel S. Acute Cardiac Injury Mediates a Distinct Form of CKD: Is This Cardiorenal Syndrome Type 7? J Am Soc Nephrol. 2025 Oct 27;36(12):2317-9. doi: 10.1681/ASN.0000000905. Online ahead of print. No abstract available.

  PMID: 41143893 DERIVED

• Funahashi Y, Hebert JF, Munhall A, Aomura D, Burfeind KG, Nguyen ED, Groat T, Nickerson MN, Eiwaz MB, Nelson JW, Andeen NK, Yanagita M, Gurley SB, Hutchens MP. Cardiac LIM Protein, Kidney Fibrosis, and Vascular Change after Acute Cardiorenal Syndrome. J Am Soc Nephrol. 2025 Dec 1;36(12):2330-2347. doi: 10.1681/ASN.0000000774. Epub 2025 Jun 19.

  PMID: 40536823 DERIVED

MeSH Terms

Interventions

Cilastatin

Intervention Hierarchy (Ancestors)

Cyclopropanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fatty Acids; Lipids

Study Officials

• Jesús Frías, MD

  Hospital Universitario La Paz

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 18, 2018
• First Posted: July 23, 2018
• Study Start: June 19, 2018
• Primary Completion: August 9, 2018
• Study Completion: August 9, 2018
• Last Updated: October 9, 2018

Record last verified: 2018-10

Locations

ES (1)